Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis
Brief Summary: Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
C: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
D: Arm Label: Cycled TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Cycled TOBI & oral ciprofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Arm Label: Culture based TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Culture based TOBI & oral cipro; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Intervention Type: DRUG; Name: Tobramycin solution for inhalation (TOBI); Assigned to Arm(s): Culture based TOBI & oral cipro, Culture based TOBI & placebo, Cycled TOBI & oral ciprofloxacin, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral placebo; Assigned to Arm(s): Culture based TOBI & placebo, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral ciprofloxacin; Assigned to Arm(s): Culture based TOBI & oral cipro, Cycled TOBI & oral ciprofloxacin

Answer: D